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SARS coronavirus (SARS-CoV) causes severe acute respiratory tract disease characterized by diffuse alveolar damage and hyaline
membrane formation. This pathology often progresses to acute respiratory distress (such as acute respiratory distress syndrome
[ARDS]) and atypical pneumonia in humans, with characteristic age-related mortality rates approaching 50% ormore in immu-
nosenescent populations. The molecular basis for the extreme virulence of SARS-CoV remains elusive. Since young and aged
(1-year-old) mice do not develop severe clinical disease following infection with wild-type SARS-CoV, a mouse-adapted strain of
SARS-CoV (calledMA15) was developed and was shown to cause lethal infection in these animals. To understand the genetic
contributions to the increased pathogenesis of MA15 in rodents, we used reverse genetics and evaluated the virulence of panels
of derivative viruses encoding various combinations of mouse-adapted mutations. We found that mutations in the viral spike (S)
glycoprotein and, to a much less rigorous extent, in the nsp9 nonstructural protein, were primarily associated with the acquisi-
tion of virulence in young animals. The mutations in S likely increase recognition of the mouse angiotensin-converting enzyme 2
(ACE2) receptor not only inMA15 but also in two additional, independently isolated mouse-adapted SARS-CoVs. In contrast to
the findings for young animals, mutations to revert to the wild-type sequence in nsp9 and the S glycoprotein were not sufficient
to significantly attenuate the virus compared to other combinations of mouse-adapted mutations in 12-month-old mice. This
panel of SARS-CoVs provides novel reagents that we have used to further our understanding of differential, age-related patho-
genic mechanisms in mouse models of human disease.
The severe acute respiratory syndrome coronavirus (SARS-CoV) is a zoonotic pathogen that emerged in Guangdong
Province in Southeast China in the fall of 2002 (10). Age was a
major cofactor enhancingmorbidity, as evidenced by50%mor-
tality rates in immunosenescent populations 65 years of age,
coupled with lowmortality rates in individuals20 years old and
medium mortality rates of 10% for the rest of the population
(58). SARS-CoV is a respiratory pathogen, and severe pathology is
found in the pulmonary system, with minor lesions/virus titers in
the liver, gastrointestinal tract, kidney, skeletal muscle, and lym-
phoid organs (23, 33, 44). The predominant pathological features
of SARS-CoV infection in the human lung are acute lung injury
(ALI) leading to diffuse alveolar damage (DAD), hyaline mem-
brane formation, and atypical pneumonia that progresses to acute
respiratory distress syndrome (ARDS), with inflammatory exuda-
tion in the alveoli and interstitial tissue and with epithelial cell
hyperplasia (6, 29, 42, 43, 58). After the acute phase, organizing-
phaseDADwith increased fibrosis is often observed (44). ALImay
progress to ARDS, an inflammatory lung disease with 50% mor-
tality rates that causes 1,000,000 deaths/year worldwide and
ranks among themost difficult challenges in critical caremedicine
(30). The mechanisms regulating disease progression are un-
known, hampering the development of therapies. Thus, a critical
need exists for robust animal models of human disease that cap-
ture acute end-stage lung disease pathologies, such as DAD and
ARDS, following acute virus infection.
SARS-CoV has a 30-kB single-stranded, positive-polarity
RNA genome that is packaged within a helical nucleocapsid com-
posed of multiple copies of the nucleocapsid protein (N) and sur-
rounded by a lipid bilayer that contains several virus glycopro-
teins, such as the 90/180-kDa spike glycoprotein, the 23-kDa M
glycoprotein, and the 12-kDaEprotein (49). Two large open read-
ing frames (ORFs) are present at the 5= end of the genome; these
are initially expressed as two large polyproteins, which are then
processed by two virally encoded proteases, the papain-like pro-
tease (PLP) (nonstructural protein 3 [nsp3]) and Mpro (nsp5),
into 16 nsp’s (nsp1 to nsp16). Among these, nsp3, nsp5, nsp9, and
nsp13 have been studied. The nsp3 gene encodes several novel
functional or predicted enzymatic activities, including the viral
protease PLP, which cleaves nsp1 through nsp3 from the ORF1a
polyprotein and has additional interferon antagonist, deubiquiti-
nation, and de-ISGylation activities (2, 20, 59). nsp5 encodes the
main protease, Mpro, which cleaves nsp4 through nsp16 from the
respective precursor polyproteins. nsp9 is an RNA binding pro-
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tein that is essential for replication, although its exact function still
remains unknown (14, 69). nsp13 contains a helicase domain that
has also been shown to be important for RNA replication (25, 70).
Although these nsp’s are clearly essential for efficient virus repli-
cation, their direct or indirect contributions to virus cross-species
transmission, adaptation, and/or enhanced viral pathogenesis are
not clear.
We have developed several robust mouse models for SARS-
CoV infection that capture the age-related disease phenotypes
seen during acute SARS-CoV infection in humans (53, 55, 56, 63).
The epidemic strain of SARS-CoV, theUrbani strain, isminimally
pathogenic in young or even aged (12-month-old) mice, as evi-
denced by limitedmorbidity and nomortality following infection
(18, 55). However, serial passage of the SARS-CoV Urbani strain
in 10-week-old BALB/cmice rapidly selected for amouse-adapted
strain of SARS-CoV (calledMA15; 15 passages before 100%mor-
tality was produced) that caused death in young and aged BALB/c
mice (53). In contrast to the effects of the SARS-CoVparent strain,
Urbani, the pulmonary pathology of youngmice infected with the
MA15 virus showed extensive damage to bronchiolar and alveolar
epithelial cells (53). Viral antigenwas highly prevalent in the bron-
chiolar epithelium, in alveolar pneumocytes, and in necrotic de-
bris deposited within the alveoli and the bronchiolar lumen of
mice. In contrast to the findings for transgenic mouse models
expressing human angiotensin-converting enzyme 2 (hACE2), no
central nervous system (CNS) involvement was observed (53). In
aged animals, these changes were more pronounced, as was also
true following SARS-CoV Urbani infection, including the devel-
opment of DAD with visible hyaline membrane formation and
inflammation scattered throughout the parenchyma (53, 63).
MA15 contains sixmutations in its genome that account for its
increased virulence in mice (53, 63). Four of these mutations re-
side in replicase proteins (2 mutations in nsp5, 1 in nsp9, and 1 in
nsp13), and 1 mutation each resides in the S and M glycoprotein
structural proteins (Fig. 1A). During the 2003 epidemic,modeling
and structural studies indicated that certain mutations in the S
protein enhanced interaction with human ACE2 and that a
K353H change in mouse ACE2 (mACE2) likely reduced the effi-
ciency of interactionwith SARS-CoV, explaining the reduced rep-
lication and disease phenotypes in mouse models (36–38, 71). In
C.
FIG 1 rMA15 viruses. (A) Genomic sequence of rMA15 showing the 6 amino acid changes found in the passaged virus. (B) Chart of rMA15mutant viruses used
in the experiments. In the mutant names, a plus sign means that the virus contains the MA15 amino acid at the position identified, and a minus sign means that
the virus contains the WT Urbani amino acid at that position. Under the protein designations, MA indicates an rMA15 mutation at the designated allele, while
WT indicates an Urbani amino acid at the designated allele. (C) Growth curves of the mutant viruses in Vero E6 cells, showing efficient replication of the
recombinant mutant viruses described in panel B.
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this report, our data suggest that the MA15 H436 mutation in the
spike glycoprotein afforded efficient interaction with mACE2 to
enhance disease outcomes inmousemodels of the human disease.
Similar adaptation through mutations of S proteins was noted
during the emergence of SARS-CoV from zoonotic precursors
during the 2002-to-2003 outbreak (19, 67). Using a SARS-CoV
molecular clone, we reconstructed a recombinantmouse-adapted
SARS-CoV (rMA15) that replicatedwith growth kinetics identical
to those of the original parent virus,MA15, in culture and induced
similar clinical disease and pathological changes (53). To evaluate
the contributions of different mutations to the pathological out-
comes seen in young and agedmice, we constructed a set of deriv-
ative recombinant viruses, each containing admixtures of wild-
type (WT) and mouse-adapted alleles, designed to identify key
residues that contributed to the development of severe clinical
disease. Our data demonstrate that the MA15 mouse-adapted
mutation in the spike glycoprotein was significantly associated
with the development of weight loss and mortality in young ani-
mals. nsp9 also had a modest but variable effect on the enhance-
ment of viral pathogenesis. In 12-month-old BALB/c mice,
rMA15 caused 100% mortality, and nearly any combination of
two or more mouse-adapted alleles tested was associated with in-
creased disease severity and mortality. Using this new model, we
identified the molecular changes present in the MA15 virus that
lead to its increased pathogenesis in young and aged mouse mod-
els of human disease.
MATERIALS AND METHODS
Bioinformatics and structuralmodeling.The amino acid sequence of the
MA15 receptor binding domain (RBD) was aligned to the SARS-CoV
Tor2 RBD sequence, for which an X-ray crystal structure has been solved
(Protein Data Bank [PDB] accession code 2AJF), using Clustal X, version
1.86. A homology model of MA15 was then generated from this align-
ment, using the Tor2 RBD sequence as a template in the Modeler pro-
gram, available as part of theMax Planck Institute Bioinformatics Toolkit
(http://toolkit.tuebingen.mpg.de/). The structural models were analyzed
and compared using MacPyMOL (Delano Scientific).
Viruses and cells. Vero E6 cells were grown in minimal essential me-
dium (MEM) (Invitrogen, Carlsbad, CA) supplemented with 10% Fetal
Clone II (HyClone, South Logan, UT) and gentamicin-kanamycin (UNC
Tissue Culture Facility). Stocks of the recombinant mouse-adapted
SARS-CoV (rMA15)were propagated; the titers were determined onVero
E6 cells; and the virus was cryopreserved at80°C until use as described
below. All viral and animal experiments were performed in a class II bio-
logical safety cabinet in a certified biosafety level 3 laboratory containing
redundant exhaust fans, and workers wore personnel protective equip-
ment, including Tyvek suits, hoods, and high-efficiency particle arrestor
(HEPA)-filtered powered air-purifying respirators (PAPRs).
Construction of the MA15 derivative recombinant virus panel. A
panel of MA15 derivative viruses was created using the previously de-
scribed infectious clone MA15 (53). The MA15 genome contains six mu-
tations that have been incorporated into the reverse genetic system for
SARS-CoV. This system consists of six plasmids that span the entire
30-kb genome of the virus. To create each of the variant viruses, the
SARS-CoV wild-type reverse genetic clone fragment was substituted for a
corresponding MA15 fragment, allowing us to create a set of viruses con-
taining various combinations of the MA15 amino acid substitutions.
The production of each virus used the previously described infectious
clone system (73). Briefly, each of the six plasmids containing fragments
of the SARS-CoV genome were cut with restriction enzymes, and the
inserted viral genome piece was gel purified from an agarose gel using
QIAquick gel purification (Qiagen). These cDNA fragments were ligated
together into a full-length cDNA, and a full-length RNA was generated
from a 5= T7 polymerase start site using mMessage mMachine as de-
scribed by themanufacturer (Ambion). Vero E6 cells were electroporated
with the different full-length genomic RNAs produced, and the virus was
isolated after 1 passage of the supernatant from electroporated cells. The
recovered virus was plaque purified and sequenced to confirm that the
correct mutations were present in each recombinant virus. All the virus
stocks produced displayed consistent phenotypes over repeated in vivo
infections ofmice, indicating that any compensatorymutations elsewhere
in the genome were not responsible for the pathogenesis phenotype ob-
served.
In vivo infections of young and aged mice. BALB/c mice were pur-
chased from Charles River at the age of 8 weeks and were used for exper-
iments at the age of 10 weeks. Aged mice were purchased from the Na-
tional Institute of Aging at the age of 12 months. Mice were anesthetized
with a mixture of ketamine-xylazine and were infected intranasally either
with the virus or with phosphate-buffered saline (PBS) in a dose of 50 l.
Virus doses ranged from 1  102 to 1  105 PFU/50-l dose, diluted in
PBS prior to intranasal administration. Animal housing and care were in
accordancewith allUNC—ChapelHill Institutional AnimalCare andUse
Committee (IACUC) guidelines and the University of Maryland at Balti-
more Institutional Animal Care and Use Committee guidelines. Infected
animals were sacrificed upon approaching 80% of their starting body
weight or manifesting severe clinical symptoms, according to the IACUC
guidelines.
Histological analysis.Lung tissueswere fixed in PBS–4%paraformal-
dehyde (pH 7.3); tissues were embedded in paraffin; and 5-m-thick
sections were prepared by the UNChistopathology core facility. To deter-
mine the extent of inflammation, sections were stained with hematoxylin
and eosin (H&E) and were scored in a blinded manner. Sections were
scored from 1 to 5 for overall inflammation, eosinophilia, neutrophilia,
alveolitis, bronchiolar denudation, and edema.
Statistical analyses. Percentages of starting weights, viral titers, and
numbers of inflammatory cells were evaluated for statistically significant
differences by the nonparametricMann-Whitney test in GraphPad Prism
or by unpaired t tests using GraphPad InStat3 software.
RESULTS
Generation of an MA15 mutant panel. The Urbani strain of
SARS-CoV was selected for increased pathogenesis after 15 serial
passages in 10-week-old BALB/c mice. The resulting mouse-
adapted virus, designated MA15, had acquired six amino acid
changes in its genome, including mutations in the replicase pro-
teins nsp5, nsp9, and nsp13 and in the S and M structural glyco-
proteins; this virus caused20%weight loss and highmortality in
mice by 5 days postinfection (dpi) (Fig. 2) (53). To identify mu-
tations that contributed to increased pathogenic outcomes, we
created a series of six recombinant viruses, each encoding five of
the six mouse-adapted mutations (Fig. 1B). The single-dropout
mutant panel was created by sequentially converting each one of
the MA15 amino acid changes back to the wild type, using the
previously described recombinant MA15 infectious clone
(rMA15) (73). The resulting panel of recombinant viruses was
designated MAN5a, MAN5b, MAN9, MAN13, MAS, and
MAM. The “MA” in each virus designation signifies the MA15
genome; “WT” is used in for the Urbani genome in virus designa-
tions. Aminus sign or plus sign signifies the addition or deletion of
the MA15 mutation at the position identified. “MAN9” means
that in the MA15 genome, the nsp9 mutation has been converted
back to the WT Urbani amino acid.
After the assembly of full-lengthmolecular clones representing
each of the recombinant viruses, full-length transcripts were elec-
troporated into cultures of Vero cells, and recombinant viruses
were isolated by plaque assays. Virus stocks were sequenced to
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verify the existence of appropriate genotypes. The six recombi-
nant virus variants and the wild-type virus were then analyzed for
their growth kinetics inVero E6 cells.Most viruses showed growth
kinetics in Vero cells similar to those of the SARS-CoV infectious
clone (icSARS) and rMA15, with only MAM displaying slightly
reduced titers 10 to 20 h postinfection (Fig. 1C, left).
Mouse-adapted mutations in the spike protein and nsp9 are
required for pathogenesis in young BALB/c mice. To identify
alleles associated with pathogenic outcomes, groups of 10-week-
old naïve BALB/c mice were inoculated intranasally with 1 105
PFU of each MA15 recombinant virus (rMA15) and were then
weighed daily (Fig. 2A). In agreement with earlier reports, mice
infected with the rMA15 parental virus lost 20% of their starting
weight during the 4 days of the infection and showed clinical signs
of disease, such as ruffled fur, labored breathing. and malaise.
Importantly, mice inoculated with MAN5a, MAN5b, MAN13,
or MAM lost 20% of their body weight over the 4 days of infec-
tion. By day 4 postinfection, these mice showed morbidities, such
as ruffling of fur and malaise, comparable to those of rMA15-
infected mice. In contrast, animals infected with the MAN9 or
MAS recombinant virus did not develop severe clinical disease or
lethal disease outcomes. MAN9-infected mice displayed a variable
phenotype, losing 10 to 20% of their starting weight, depending on
the mouse. Most did not succumb to infection, suggesting that the
mouse-adapted allele in the nsp9 gene may subtly influence severe
disease phenotypes. Most importantly, MAS-infected mice uni-
formly lost less than 5% of their starting weight, showed no visible
clinical signs of disease, and did not die. These data suggest that the
MA15 allele in the S glycoprotein receptor binding domain (S-RBD)
contributed significantly to increased disease in rodents, most likely
by enhancing interactions with mouse ACE2 receptors (see Fig. 9).
These results are consistent with a large body of data supporting the
notion that S glycoprotein-host receptor interactions are a key regu-
lator of emergence, tissue tropism, and species specificity, especially
for SARS-CoV and other animal and human coronaviruses (1, 7, 21,
36, 61, 62, 66).
FIG 2 Pathogenesis of rMA15mutant viruses in young BALB/c mice. (A) Percentages of weight loss for mice infected with rMA15 variant viruses. MAN9- and
MAS-infected mice show reductions in weight loss during infection. Ten mice per time point per virus were used. (B) Titers of rMA15 variant viruses at 2 and
4 dpi in the lung. Titers in lung sampleswere determined onVero E6 cells. Five experimentswere carried out for each virus and time point. (C) Lung sectionswere
stained with H&E and were scored for the amount of inflammation in each section. Scoring was carried out five times for each time point and virus. (D) Images
of representative H&E-stained lung sections at 2 and 4 dpi.
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To identify potential correlates of pathogenicity, lungs from
infected mice were homogenized, and virus titers were deter-
mined on days 2 and 4 postinfection (Fig. 2B). Interestingly, the
titers of all mutant viruses were similar to those of rMA15. How-
ever, MAS virus titers were reduced, to a level about 3-fold lower
than the rMA15 titer, at day 2 (P  0.05). At 4 days dpi, the
differences in replication were more significant, with MAS dis-
playing a titer 100-fold lower than that of rMA15 (P 0.05). We
did not detect any other significant differences in virus titers with
the remaining derivative recombinant viruses.
Pathological findings. We have reported a histological analy-
sis of the lungs of mice infected with the rMA15 virus previously
(53). We found that mouse lungs displayed rapid progression of
inflammation, with extensive damage to the bronchiolar and al-
veolar epithelial cells. Histological analysis performed with the
mutant viruses across the course of infectionwas compared to our
previous findings. After fixation in 4% paraformaldehyde, lungs
were sectioned and stained with H&E. Scoring was performed for
total inflammation at 4 dpi (Fig. 2C andD). rMA15-infectedmice
showed increased overall inflammation characterized by peri-
bronchiolar cuffing and a mixed inflammatory infiltrate consist-
ing of neutrophils, eosinophils, and macrophages. The lungs also
showed evidence of denuding bronchiolitis, focal alveolitis, focal
apoptosis of the airway epithelia, and blockage of the airways with
apoptotic debris. Histological analysis of mice infected with the
mutant panel showed very similar inflammatory infiltrates and
damage to the rMA15 virus. Interestingly, the MAN9 and MAS
viruses displayed no difference in lung pathology fromWTMA15
over the course of the infection, even though the mice displayed
marked differences in weight loss from rMA15-infectedmice. The
observation that MAS exhibited levels of lung pathology similar
to those for WT MA15 despite a log reduction in viral titer (Fig.
2B) indicated that other signaling events may be involved in en-
hancing lung pathology. Similar discrepancies between viral rep-
lication and lung pathology have been noted in the pathogenesis
of another coronavirus, HC/SZ/61/03 (57).
Dependence on spike and nsp9 mouse-adapted virus muta-
tions for pathogenesis. The data reported above support the hy-
pothesis that the rMA15 pathogenesis phenotype depended heav-
ily on the mutation in the S structural glycoprotein and to a much
lesser extent on that in the nsp9 replicase protein. We next exam-
ined whether the S and nsp9 mutations were individually suffi-
cient to reproduce the rMA15 pathogenic phenotype in 10-week-
old mice. For this purpose, a second panel of derivative isogenic
viruses that contained either the MA15 nsp9 mutation or the S
glycoprotein mutation alone, designated WTN9 or WTS, re-
spectively, was constructed on an Urbani virus backbone.We also
constructed recombinant viruses containing both theMA15 S and
nsp9 alleles (designated WTN9/S) while maintaining the wild-
typeUrbani alleles at the other four positions. In parallel, a recom-
binant virus that contained four mouse-adapted mutant alleles
but retained thewild-typeUrbani alleles in the nsp9 and Sproteins
(designated MAN9/S) was constructed (Fig. 1B).
Full-length molecular clones were assembled as described pre-
viously, and recombinant viruses were produced (73). Each virus
was plaque purified and was sequenced to verify the existence of
each appropriate genotype. Then the growth of the recombinant
viruses inVero cells was analyzed andwas compared to the growth
of MA15 in vitro (Fig. 1C). These variants showed robust growth,
equal to that seen with the rMA15 virus. These data suggest that
epistatic interactions across the mutations are minimal in vitro,
since all recombinant viruses tested replicated efficiently in Vero
cells.
TheMA15derivativeswere assayed for associated pathogenesis
and mortality in 10-week-old BALB/c mice. Groups of mice were
inoculated intranasally with a dose of 1 105 PFU given intrana-
sally under sedation, as described previously (54). The rMA15
virus produced rapid weight loss, resulting in reductions of20%
of the animals’ starting weight by 4 dpi. Like mock-infected con-
trols, mice infected with the WTN9/S, MAN9/S, WTN9, or
WTS variant failed to lose weight during infection or to show
other clinical signs of disease (Fig. 3A). Lungs were analyzed for
virus titers, and interestingly, all recombinant virus derivatives
showed titers similar to those of the rMA15 virus in the lungs at
days 2 and 5 postinfection. Histopathological analysis of the lungs
revealed no significant differences from the lungs of mock-
infected animals (data not shown). While the MA15 alleles in the
S glycoprotein gene and, to a lesser extent, in the nsp9 gene are
clearly important contributors to replication and MA15 patho-
genesis in vivo, as evidenced by the fact that their removal amelio-
rated the virulence of rMA15, these alleles clearly depend on the
presence of one or more additional MA15 mutations in the Ur-
bani virus to cause significant disease in young BALB/c mice.
Immunosenescence differentiallymodulates the pathogene-
sis of the MA15 derivative viruses. In humans, age was a major
cofactor associated with disease severity following SARS-CoV in-
FIG 3 rMA15 nsp9 and spike mutants in young mice. (A) Percentages of
weight loss for mice infected with the rMA15 variant viruses diagramed in Fig.
1B. Note that young mice infected with the nsp9 or S variant show no weight
loss, while those infected with rMA15 do. Five experiments were carried out
for each virus. (B) Titers of rMA15 variant viruses in the lungs at 2 and 4 dpi.
Titers in lung samples were determined on Vero E6 cells. Note that there was
no difference betweenWT and mutant viruses. Five experiments were carried
out for each virus.
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fection (45, 48). In contrast to youngmice infectedwith a 105-PFU
dose of SARS-CoV Urbani, 1-year-old mice show a mild clinical
disease phenotype that includes 5% weight loss and increased
virus titers, although the animals survive infection (53). Impor-
tantly, 1-year-old mice are also significantly more sensitive to
rMA15 pathogenicity; rMA15 infection of 1-year-old mice results
in increased disease pathology, including pathological findings of
acute-phase diffuse alveolar damage characterized by hyaline
membrane formation, recapitulating the pathological features
commonly noted in human patients infected with SARS-CoV
(63). Moreover, the aged-mouse model supports high levels of
viral replication. Reasoning that the aged-mouse model would
provide a more sensitive measure of the role of individual muta-
tions in virulence and disease outcomes, we compared the repli-
cation and pathogenicity of the rMA15 derivatives in 1-year-old
mice.
First, we examined the pathogenicity of rMA15 and the previ-
ously described MASM and WTSM viruses (Fig. 4A) in 12-
month-old BALB/c mice (53). These recombinant viruses carry
either the MA15 replicase mutant alleles or the structural glyco-
protein S and M mutant alleles, respectively, and do not produce
clinical disease and/or death in young (10-week-old) animals (53).
With an inoculum of 1  105 PFU, all 1-year-old mice demon-
strated severe disease by 4 dpi, losing 20% of their starting
weight (Fig. 4B). During the course of the infection, all mice
showed signs of clinical disease, including ruffling of fur, labored
breathing, and lethargy. Lungs were harvested at 2 and 4 dpi for
determination of virus titers and histopathological analysis. Im-
portantly, no significant difference in growth between the rMA15,
MASM, and WTSM viruses was noted at 2 or 4 dpi in aged
BALB/cmice (Fig. 4C). Virus titers in the lung at day 2 approached
108 PFU/g, while day 4 titers were106 PFU/g.
Lungpathologywas analyzed byH&E staining (Fig. 4D). Lungs
harvested from mice at 2 and 4 dpi showed pathology similar to
that in mice infected withWTMA15 (63). At 2 dpi, lungs showed
epithelial cell necrosis, airway debris, and mild peribronchiolar
cuffing composed of neutrophils, lymphocytes, andmacrophages.
At 4 dpi, lungs demonstrated sustained inflammation and inflam-
matory cell infiltrates with widespread injury of the alveolar pa-
renchyma, interstitial edemawith hyalinemembranes, and diffuse
alveolar damage. Clearly, the attenuated phenotype of theMASM
and WTSM viruses seen in young BALB/c mice was not recapit-
ulated in the aged-mouse model, suggesting that fewer and differ-
ent combinations of MA15mutations regulate severe disease out-
comes in 1-year-old mice.
Lethality of spike and nsp9 mutants in aged mice. In young
(10-week-old) BALB/c mice, the MAN9 and MAS viruses were
highly attenuated compared to the MA15 parent strain. Thus, we
tested the virulence of these mutants in 12-month-old BALB/c
mice with the goal of identifying mutation sets that differentially
regulate severe disease outcomes in young and aged mouse mod-
els. As previously described, a 1 105-PFU inoculum was intro-
duced intranasally into groups of BALB/c mice, and then clinical
disease phenotypes were evaluated over the course of infection.
We observed that aged mice were as highly susceptible to the
MAN9 andMAS recombinant viruses as theywere to the rMA15
virus (Fig. 5A). Animals lost20% of their starting weight during
the 3 days of infection and were euthanized according to IACUC
weight loss criteria. Lungs were harvested at day 3 postinfection
due to the severe weight loss of the mice. Minor differences in
FIG 4 Pathogenesis of rMA15 genome variants in aged mice. (A) Chart
showing rMA15 variant viruses encoding only the structural mutations or
only the replicase mutations. (B) Percentages of weight loss for mice in-
fected with rMA15 variant viruses. Note that the variants are as pathogenic
as rMA15 virus in old mice. Five experiments were carried out for each
virus and time point. (C) Titers of rMA15 variant viruses in the lung at 2
and 4 dpi. Titers in lung samples were determined on Vero E6 cells. Note
that there was no difference in lung virus titers among the variants and the
wild type. Five experiments were carried out for each virus and time point.
(D) Images of representative H&E-stained lung sections at 2 and 4 dpi.
Note the high levels of eosinophil and neutrophil infiltration in the lungs of
infected mice.
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titers were found, but these differences were not statistically sig-
nificant (P  0.05) (Fig. 5B). The histological findings did not
differ significantly from those for the parent virus (Fig. 5C). The
predominant pathological feature was denuding bronchiolitis
with accumulation of debris in the airways. Inflammatory infil-
trates (e.g., neutrophils, macrophages, lymphocytes) surrounded
and penetrated the airway epithelium, and perivascular cuffing
was prominent. The lung parenchyma displayed focal inflamma-
tory foci consisting of neutrophils and eosinophils with alveolar
thickening and overall high levels of cellularity. Hyaline mem-
branes and diffuse alveolar damage were evident. We conclude
that MASM, WTSM, MAN9, and MAS variants are also fully
virulent in the 1-year-old mouse model, demonstrating that dif-
ferent combinations ofmouse-adaptedmutations recapitulate se-
vere disease outcomes in the lung that are seen following infection
in humans (45). Together, these results suggest that most mouse-
adapted mutations enhance intrinsic pathogenic properties en-
coded in the viral genome and that aged mice differ from young
mice in their ability to respond to, and induce protection from,
viruses that are attenuated in young mice.
The spike and nsp9 mutations together are necessary and
sufficient to regulate pathogenesis in aged mice.We next evalu-
ated the role of the mouse-adapted nsp9 and S mutations in age-
related disease outcomes. The viruses used contain reciprocal
combinations of S and nsp9 mutations in either the Urbani or the
MA15 background.
We compared the pathogenicity of WTN9/S, MAN9/S,
WTN9, andWTS in agedmice (viruses described in Fig. 1B). As
described previously, 12-month-old BALB/c mice were inocu-
latedwith 1 105 PFUof each virus, and clinical disease outcomes
were evaluated daily. In young BALB/c mice, all of these mutants
were attenuated. However, in aged mice, disease phenotypes dif-
fered with each mutant (Fig. 6A). In comparison to the effects of
rMA15 on 12-month-old BALB/cmice, SARS-CoVUrbani causes
5%weight loss, grows to a lower titer in the lungs, and causesmild
inflammation. The mutant virusesWTN9/S andMAN9/S caused
significant weight loss and death in 1-year-old mice. Compara-
tively, recombinant virus WTN9 or WTS caused only mild
weight loss and clinical disease. Importantly, WTS did cause
some mortality (2/8 mice), especially when the experiment was
extended through 7 days. The titers of rMA15 and MAN9/S in
lungs at 4 dpi were similar, while WTN9/S, WTN9, and WTS
demonstrated10-fold-higher titers (Fig. 6B). Histological anal-
ysis was performed on the lungs of these mice, and only slight
differences between the strains were noted; the lungs displayed
pathological features described previously for agedmice (55) (Fig.
6C). Interestingly, MAN9/S showed a tendency toward greater
hyaline membrane formation, although this was not a statistically
significant difference (Fig. 6C). Additionally, WTN9 displayed
focal eosinophilia at a frequency slightly (but, again, not statisti-
cally significantly) higher than those for the other mutants. These
data further demonstrate that the S and nsp9 mutations together,
as seen inWTN9/S, or in combinationwith the other fourmouse-
adapted mutations, are sufficient to cause disease similar to that
caused by rMA15 in aged mice. However, when the S and nsp9
mutations are the sole mutations in the SARS-CoV genome, the
mutants are significantly less virulent in old mice, suggesting that
there are unique virus-host interactions in oldmice with the other
MA15 mutations that are important for disease progression and
pathogenesis.
We next infected 12-month-old mice with varying amounts of
each MA15 derivative virus so as to better identify unique patho-
genic phenotypes for each of the mutant viruses. Mice were in-
fected withWTN9/S, MAN9/S, orWTS at doses of 1 102 PFU,
FIG 5 MA15 S and nsp9 variant viruses in aged mice. (A) Percentages of weight loss for mice infected with MA15 variant viruses. Aged mice infected with the
MAN9 or MAS virus display weight loss similar to that with rMA15. Five experiments were carried out for each virus and time point. (B) Titers of rMA15
variant viruses in the lung at 2 and 3 dpi. Titers in lung samples were determined on Vero E6 cells. Note that there was little difference in lung titers among the
variants and the wild type at either 2 or 3 dpi. Five experiments were carried out for each virus and time point. (C) Images of representative H&E-stained lung
sections at 2 and 3 dpi. Notice the high levels of inflammation and infiltration in these lungs. Airways display continued inflammation throughout the infection.
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1  103 PFU, 1  104 PFU, or 1  105 PFU per mouse. With
rMA15, a dose of 1 102 PFU is fully pathogenic and virulent in
aged mice; the mean day of death is day 5.4  0.54 (Fig. 7A and
Table 1). In contrast, the mutant viruses WTN9/S and MAN9/S
were significantly less virulent at a low dose (1 102 PFU/mouse),
and all mice survived infection. However, after high-dose infec-
tion (1 105 PFU/mouse), the WTN9/S and MAN9/S derivative
mutants were as lethal as rMA15. Importantly,WTS, which con-
tains only the mouse-adapted S mutation, also was not lethal at
low doses; however, inoculation with 1  105 PFU per mouse
resulted in some lethality. Interestingly, the 50% lethal doses
(LD50) for the WTN9/S and MAN9/S viruses were higher than
that for rMA15 (Table 1). This observation indicated that al-
though the nsp9 mutation and especially the S mutation are im-
portant contributors to pathogenicity in old mice, additional
MA15 mutations are needed to enhance disease progression and
death. A recent report by Ebihara et al. identified a similar increase
in the LD50 in a derivative panel of mouse-adapted Ebola viruses,
where the variant containing mouse-adapted mutations in the
nucleoprotein (NP) and viral protein 24 (VP24) could still cause
lethality, but the LD50 was increased 5-fold (11). These observa-
tions together indicate that although key mouse-adapted muta-
tions alone could impart lethality, a complete set of mouse-
adapted mutations collectively regulate pathogenesis.
We conclude that while highly attenuated in young mice, the
rMA15 viruses with both nsp9 and S MA15 mutant alleles are
capable of causing severe disease outcomes and death in aged
mice. Viruses with only the nsp9 mutant allele are not fully viru-
lent in 1-year-old mice, while the virus with only the S MA15
mutant allele is still moderately pathogenic in 1-year-old mice,
especially at higher doses. These data suggest that the expression
or functional activity (e.g., senescence) of one or more cellular
factors mediates differential disease outcomes in young and aged
mice.
Novel mouse-adapted SARS-CoVs produce similar disease
in mice.Our data indicated that host senescence significantly en-
hanced the virulence of rMA15 and the derivative recombinant
virus panel, in agreement with the pathological phenotypes seen
in human SARS-CoV infections. Mouse adaptation may enhance
intrinsic pathogenic properties encoded in the SARS-CoV and/or
evolve new virus-host interactions and signaling networks that
promote disease severity. Because the analysis of each of these
SARS-CoV mutants depends on the initial identification of a
mouse-adapted strain of the virus, we wanted to determine
whether this mouse-adapted strain was unusual in its adaptation.
For this purpose, we isolated an additional mouse-adapted strain
of SARS-CoV, designatedMA20, and determined whether similar
adaptive mutations had evolved after independent selection
and/or produced similar disease outcomes in young and aged an-
imals. MA20 wasmouse adapted after 20 independent serial blind
passages at 2-day intervals in 10-week-old BALB/c mice and en-
coded six amino acid changes that were associated with increased
virulence. Day et al. have also recently published the sequence of a
novel mouse-adapted strain of SARS-CoV, called v2163 (8).
Strain v2163 was isolated from the serial passage of SARS-CoV
Urbani in 6-week-old BALB/c mice and contains 10 amino acid
changes in its genome. Comparing the 3 independently isolated
mouse-adapted viruses, we foundmutated genes common to all 3
(nsp13, Spike),mutated genes common to 2 of the 3 viruses (nsp5,
M), and genes that were mutated in only a single virus (nsp3,
nsp14, 3b/E) (Fig. 8A). First, an identical M glycoprotein muta-
tion (E11K) evolved in both theMA15 andMA20mouse-adapted
viruses. Remarkably, the S-RBD contained a series of related and
unique mutations in all three strains. The mutations clustered at
the interface between the RBD and the ACE2 receptor and are
predicted to affect RBD interaction with the orthologous mouse
ACE2 receptor used for docking and entry (Fig. 8 and 9). In addi-
tion, both MA15 and v2163 have evolved mutations in nsp9 that
localize at different but nearby positions. These clustered muta-
tions support the hypothesis of a role for these genes in mouse
adaptation and disease potential, especially in young animals.
To compare disease outcomes with the three mouse-adapted
viruses, we infected 10-week-old BALB/c mice with 1 105 PFU
each, or with PBS as a control, and weighed the mice daily (Fig.
8B). All three viruses caused similar weight loss kinetics during the
experiment: themice lost20%of their starting weight over the 4
days of infection. Lungs were dissected from mice at 2 and 4 dpi,
FIG 6 MA15 S and nsp9 combination variant viruses in aged mice. (A) Per-
centages of weight loss ofmice infected with rMA15 variant viruses. Agedmice
infected with WTN9/S or MAN9/S display weight loss similar to that with
rMA15. Five experiments were carried out for each virus. (B) Titers of virus in
the lungs at 4 dpi were normal for MAN9/S and WTN9, while WTS and
WTN9/S demonstrated 1-log-lower titers. Five experiments were carried
out for each virus and time point. (C) Images of representative H&E-stained
lung sections at 4 dpi.
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and viruses were quantified by plaque assays (Fig. 8C). No signif-
icant differences in virus titer were noted following infection with
the three mouse-adapted viruses at either day 2 or day 4 postin-
fection. MA20 caused disease pathology similar to that caused by
MA15 and v2163, revealing no significant differences in lung pa-
thology between the three strains (data not shown). These data
support the hypothesis that common mutations allowing for in-
creased pathogenicity and disease in a host are acquired in the
SARS-CoV, and they suggest that important virus-host interac-
tions occur during infection.
DISCUSSION
Virus passage in vivo, and mouse adaptation in particular, is a
common strategy used to develop robust animal models for hu-
man disease (e.g., Ebola virus [11], Marburg virus [5], hantavi-
ruses [4, 28, 35], respiratory syncytial virus [RSV] [24], human
coronaviruses [32, 53], dengue virus [64, 65], yellow fever virus
[15]), poliovirus [31], and influenza virus [27]. This necessary
step reflects basic findings that many viruses cause significant dis-
ease outcomes in humans butmild orminimal clinical disease and
pathology in rodents. While potentially complicating compari-
sons across mouse and human species, mouse-adapted viruses
afford access to a wealth of reagents developed for the laboratory
mouse, including access to genetically defined mutants. In this
study, we use a reverse genetic approach to identify the genetic
determinants of mouse-adapted SARS-CoV that regulate viru-
lence in young and 1-year-oldmice. Threemouse-adapted strains
of SARS-CoV (MA15, v2163, andMA20) have nowbeen indepen-
dently isolated and reported in the literature. Among these, the
pathogenesis of MA15 has been extensively studied by transcrip-
tomics and disease outcomes in genetically defined knockoutmice
and in young and aged mouse models of human disease (17, 53,
60, 74, 75), providing considerable insight into key virus-host in-
teractions that differentially regulate disease processes and patho-
genic outcomes following infection. More recently, transgenic
mice expressing the humanACE2 receptor used by SARS-CoV for
FIG 7 (A to C)Dose-response curves of rMA15 variant viruses in agedmice.WTMA15, as well asWTN9/S (A),MAN9/S (B), andWTS (C), was used to infect
agedmice with different doses of virus. (D to F) Survival curves are plotted alongside each dose-response curve. Five experiments were carried out for each virus.
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virus docking and entry have provided an alternative approach for
developing mouse models of SARS-CoV pathogenesis (39), al-
though these mice also develop a lethal neurologic disease, which
is rarely seen in human SARS patients. While both approaches
provide considerable insight into the molecular mechanisms gov-
erning virus pathogenesis (e.g., poliovirus [52] and measles virus
[22, 51]), few models are available that simultaneously compare
and contrast mutation spectra after cross-species transmission
from animals to humans (wild-type SARS-CoV from bats and
civets) and from humans to animals (human viruses to mouse-
adapted viruses) and the development of severe disease outcomes.
Moreover, few studies have sequentially reisolated mouse-
adapted strains to identify the spectrum of shared and unique
molecular determinants that regulate host adaptation and disease
phenotypes in young and/or aged animal models of human dis-
ease.
Most human coronaviruses replicate poorly in mice, resulting
in the selection of mouse-adapted strains for pathogenesis studies
in small animals (OC43 and 229E) (3, 26, 32). SARS-CoV is a
highly pathogenic respiratory coronavirus that emerged from
zoonotic sources in China in 2003, providing a unique opportu-
nity to compare and contrast the molecular determinants that
regulate virus evolution, adaptation, and virulence in new species
by using humans and mice as models. Importantly, the epidemic
strain of SARS-CoV (the Urbani strain) replicates and produces
minimal disease inmice; however, this provides an opportunity to
model, compare, and contrast the evolution of virulence-
enhancingmutations in rodent and human hosts. In this capacity,
we sought to identify the mutations that are necessary and suffi-
cient to cause the lethal disease produced byMA15, enabling us to
elucidate the important molecular determinants regulating virus-
host interaction and virulence in young and aged animal models
of human disease.
Infection with MA15 mutants, each lacking one change in the
parental mouse-adapted virus, demonstrated that mutations in
the replicase nonstructural protein nsp9 and the spike glycopro-
tein contributed to increased SARS-CoV pathogenesis in young
mice (Fig. 2 and 5). Attesting to the importance of these proteins
in viral pathogenesis, other, independently derived mouse-
adapted SARS-CoV strains also displayed mutations in these
genes, as evidenced by nsp9 mutations in MA15 and v2163 and
S-RBDmutations that emerged in all threemouse-adapted strains
(Fig. 7A). To further our understanding of the role of these mu-
tations in pathogenesis, we introduced the nsp9 and S mouse-
adapted virus mutations into icSARS (Urbani) either singly or in
combination. In young animals, recombinant viruses with either
the single or double mutations at these positions replicated to
higher titers but did not producemore-severe clinical disease than
did the wild-type virus (Fig. 3A and B). These data suggest that the
mutation in the S glycoprotein plays a prominent role, while the
influence of the nsp9 mutation is more variable. The mutations,
alone or in combination, are necessary but not sufficient to cause
disease in young mice. In agreement with this hypothesis, inde-
pendent generation of three mouse-adapted SARS-CoVs resulted
in mutations in genes encoding the M glycoprotein and the repli-
case protein nsp13. Two of threemouse-adapted viruses also con-
tained mutations in nsp5 (Mpro) (Fig. 8A), and sporadic muta-
tions were identified in either nsp3 or nsp14. Among these
mutations, previous studies had suggested that a mutation at po-
sition 11 (E11K) in theMA15Mglycoprotein gene enhanced virus
yields in cells, suggesting a key role in improving the efficiency of
virus maturation and release in different hosts (46). Mutations in
themouse hepatitis virus (MHV) nsp14 gene, encoding a putative
RNA proofreading function and 7-0-methyltransferase, were also
shown to attenuate pathogenesis in mice, supporting the role of
nsp14 as a putative virulence allele (9, 13, 50, 68). It is noteworthy
that mutations in the S and M glycoprotein genes were also ob-
served during cross-species transmission of SARS-CoV to hu-
mans, suggesting commonalities in the regulation of virulence in
the two species. Othermutations associatedwith the emergence of
human disease also evolved in the ORF1a nonstructural proteins
nsp1, nsp2, and nsp3, as well as in the ORF1b nonstructural pro-
teins nsp13, nsp14, and nsp15 (7). Although the sites are different,
mutations in nsp3, nsp13, and nsp14 also evolved during mouse
adaptation. Similar observations have been noted in mouse-
adapted Ebola virus, where a combination ofmutations inNP and
VP24 is essential for lethality in young BALB/cmice, though none
of these individual mutations alone could impart pathogenicity
(11). Based on precedents from other systems, likely functions of
these mutations may be to enhance virus replication in mice, en-
gage host innate immune signaling networks, influence RNA fi-
delity rates, and/or ablate interferon-stimulated antiviral gene ac-
tivities (9, 12, 16, 34, 41).
Themouse ACE2 receptor interacts weakly with epidemic (Ur-
bani) strain S glycoprotein RBDs in vitro in biochemical studies
and in studies with pseudotyped viruses (71, 72) (modeled in Fig.
9). This is most likely because a K353H difference in mACE2 re-
models the interactions between residues D38, Q42, and H353 of
mACE2 and residue Y436 of the Urbani RBD, the bulky aromatic
TABLE 1 Fifty percent lethal dose and mean day of death for 1-year-old
female BALB/c mice infected intranasally with the indicated
dose of virusa
Virus and dose LD50 Mean day of death
MA15 102
102 5.4 0.54
103 4.6 0.54
104 4.2 1.3
105 3.8 1.09
WTN9/S 102.5
102 NAb
103 4.4 0.54
104 4.8 1.09
105 3.2 0.44
MAN9/S 102.3
102 NA
103 5.6 1.51
104 4.4 1.14
105 3.2 0.4
WTS 104.375
102 NA
103 NA
104 NA
105 6 1.26
a Viruses used were the mouse-adapted SARS-CoV (MA15) and mutant derivatives of
MA15 and wild-type SARS-CoV Urbani. For each dose of each virus, five animals were
infected.
b NA, not applicable.
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side chain of which potentially reduces binding. Mutation of
His353 to K in mACE2 allows more-efficient infectivity of SARS-
CoV for murine cells (36). In accordance with our understanding
of coronavirus-receptor interactions and host range, mutations in
the RBD of the S glycoprotein were positively selected during the
adaptation of MA15, MA20, and v2163 to mice and during
zoonotic-strain adaptation to humans. As was predicted during
the human epidemic, modeling studies strongly support the hy-
pothesis that these three unique mutation sets enhance viral
S-RBD interaction with the mACE2 receptor, primarily by allow-
ing for efficient recognition ofD38 or a polar region established by
mACE2 N30, N31, and Q34 at the viral S-RBD–ACE2 interface
(Fig. 9). Previous studies have identified 13 contact residues in the
SARS-CoV RBD, including residue Y436, which interacts with
ACE2 residues D38 and Q42, sites that are identical in the mouse
and human receptors (40, 71). Of note, the K353H difference in
mACE2 also contributed to this remodeling, since this change
likely allowed D38 to interact with H436 more efficiently. In con-
trast, MA20 evolved changes at Y442L and N479K in the RBD,
which likely form polar interactions with two asparagine residues
at positions 30 and 31 ofmACE2. In addition, the Y442L change in
theMA20 RBD removes the bulky aromatic side chain of tyrosine,
allowing K479 of the MA20 RBD access to binding partners N30
and N31 of mACE2. Finally, v2163 evolved the K411E, Y436H,
and Y442F mutations in the RBD. Structural modeling suggests
that v2163 encodes adaptations that target both sites that adapted
in MA15 andMA20. The observation that v2163 optimized bind-
ing to two sites on mACE2 suggests that v2163 may have a higher
binding affinity for the mACE2 receptor than MA15 and/or
MA20, a feature that may have been required for enhancing
pathogenesis in 6-week-old mice. Structural and biochemical
studies will be needed to confirm these models.
The emergence of several unique evolutionary pathways that
enhance mACE2 usage attests to the flexibility of the RBD-ACE2
interface, in agreement with earlier studies in our laboratory,
which identified several mutation pathways that promote the rec-
ognition of the hACE2 receptor by civet strain SZ16 (62). Of note,
mutations in the RBD of the S glycoprotein of MA15 were abso-
lutely essential for enhanced pathogenesis in young animals.
These data are also consistentwith earlier studies in our laboratory
that demonstrated that recombinant isogenic SARS viruses en-
coding early human and civet S glycoproteins led to enhanced
disease in aged mice (56). Surprisingly, some of the MA15molec-
ular determinants that regulated enhanced virulence and patho-
genesis in aged animals were overlapping while others were
unique, supporting earlier hypotheses that host factors played a
FIG8 Comparative pathogenesis of threemouse-adapted SARS-CoVs. (A) Schematic ofmutation differences among rMA15,MA20, and v2163. (B)Weight loss
curves for young mice infected with MA15, MA20, or v2163. Five experiments were carried out for each virus. (C) Virus titers in the lungs of mice infected with
rMA15, MA20, or v2163 at 2 and 4 dpi. Five experiments were carried out for each virus and time point.
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critical role in regulating SARS-CoV virulence and pathogenic
outcomes (17, 56, 63, 75).
SARS-CoV produced asymmetric disease outcomes in young
and 1-year-old animals, as evidenced by increased virus titers,
more-severe disease outcomes, reduced LD50 values, and higher
mortality rates in aged populations; similar results have been re-
ported for humans65 years of age (29). Fatal and severe disease
outcomes for the elderly have also been reported with other hu-
man coronaviruses, such as OC43 (47). The molecular mecha-
nisms governing age-related disease susceptibility are unclear but
have generally been linked to a progressive age-related senescence
of the immune system and perhaps other key cellular activities
that participate in virus-host interactions and disease (56). Studies
reported here and previously clearly demonstrate that SARS-CoV
and MA15 virulence and pathogenesis are exquisitely sensitive to
aging processes in humans and mice, and in contrast to other
mousemodels of immunosenescence, virulence is clearly visible in
1-year-old mice. In rMA15 infection of aged versus young mice,
the LD50 drops from104 to 102 PFU and from106 to 102 PFU
for the BALB/c and C57BL/6 strains, respectively (63). In young
mice, pathological changes include acute denuding bronchiolitis,
perivascular cuffing, andmild alveolitis. In contrast, aged animals
display similar but more-severe airway and vascular changes, in-
cluding more severe-cuffing and pneumonia with neutrophils,
macrophages, lymphocytes, and scattered eosinophils, diffuse al-
veolar damage, and hyaline membranes, symptoms that are
prominent in severe human infection. Additionally, we observed
an interesting difference in pathogenesis among the mutant vi-
ruses in youngmice.MAS produced virus titers and lung pathol-
ogy equal to those produced by the other singlemutant viruses but
did not induce weight loss in youngmice.We hypothesize that the
interaction of the mouse-adapted spike protein with its mACE2
receptormay alter the signaling and host response from thosewith
human ACE2, leading to the differences in virus titer and weight
loss. Further experiments are needed to follow up this hypothesis.
Finally, virulence in young animals appears to require the co-
ordinated evolution of 6 to 10 mutations, including critical ge-
netic determinants in the S glycoprotein that are likely augmented
by mutations encoded elsewhere in the genome. In contrast, the S
glycoprotein mutation alone, as well as many different combina-
tions of the other mutations, produced lethal disease outcomes in
1-year-old mice. To our knowledge, comparative pathogenesis of
mouse-adapted viruses as a function of age has not been demon-
strated previously in the literature. Disease patterns in aged mice
replicated pathological outcomes and clinical disease symptoms
seen following infection with the MA15 parent virus. These phe-
notypes included similar virus titers and increased lung pathol-
ogy, mimicking the severe disease phenotypes seen during human
infections in aged, but not young, populations. These data clearly
demonstrate that different viral determinants influence patho-
genic outcomes in young and aged mouse populations.
Molecular determinants have been precisely mapped for many
mouse-adapted viruses, yet MA15 is unique in that several over-
lapping and/or completely different sets of mouse-adapted muta-
tions produce lethal disease outcomes in aged, but not young,
animals. These outcomes could be explained by the presence of
FIG 9 Structural comparison of mouse-adapted SARS-CoVmutations and ACE2. (A) Interactions between the Urbani RBD (blue) and human ACE2 (green).
The residues in the RBD that change during adaptation to mouse ACE2 are highlighted (cyan). The human ACE2 residues that interact with those RBD sites are
shown in red. A key electrostatic interaction occurs between D38 and K353 of human ACE2 (weakened in mouse ACE2). (B) Interactions between the Urbani
RBD (blue) and mouse ACE2 (tan). The residues in the RBD that change during adaptation to mouse ACE2 are highlighted (cyan). The mouse ACE2 residues
that likely interact with those RBD sites are shown in red. (C) Adaptation of MA15 to mACE2. The Y436H change allows MA15 to interact more robustly with
mACE2, since Y436H likely increases binding via electrostatic interaction with D38 of mouse ACE2. Purple, MA15 RBD; tan, mouse ACE2; yellow, residue that
changed inMA15; red, residues interactingwithRBD sites that adapted tomACE2. (D)Adaptation ofMA20 tomACE2. TheY442L andN479K adaptations allow
these residues to interact with N30, N31, and Q34 of mACE2, likely increasing binding affinity. MA20 K479 can bind to both N30 and N31 of MA20 via polar
interactions, and MA25 L442 likely interacts with Q34 of mACE2. Green, MA20 RBD; tan, mouse ACE2; yellow, residue that changed in MA20; red, residues
interacting with RBD sites that adapted to mACE2. (E) Adaptation of MA25 to mACE2. As with MA15, the Y436H change likely allowed this residue to interact
more robustly with D38 of mACE2, with the K353H difference in mACE2 playing a key role. In addition, the Y442F adaptation removes a hydroxyl group from
the binding interface, likelymediating a better fit betweenMA25 andmACE2. Purple,MA25 RBD; tan, mouse ACE2; yellow, residue that changed inMA20; red,
residues interacting with RBD sites that adapted to mACE2.
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different sets of mutations that differentially influence virus rep-
lication and/or host signaling networks in young and aged ani-
mals. Alternatively, thesemutationsmay simply increase viral rep-
lication and thereby enhance the effect of intrinsic virulence
determinants encoded in the SARS-CoV genome. These effects
can be further enhanced as a result of immunosenescence and
aging of the host. Dissection of the host response pathways that
differentially regulate the disease outcome in young and aged pop-
ulations not only would shed light on host-pathogen interactions
important during SARS-CoV infection of humans but may also
identify early markers of immunosenescence. Detailed genomic
analyses of recombinant viruses containing the mouse-adapted
nsp9 or Smutation alone or with other alleles will also be essential
for dissecting the roles of these mutations in pathogenesis.
We have mapped the molecular determinants in mouse-
adapted SARS-CoV that recapture humandisease phenotypes and
age-related disease outcomes, including enhanced lung pathol-
ogy. We have also shown that the mutations work in concert and
are critical for the disease progression of SARS-CoV in both young
and old mouse models. Experiments with passage of SARS-CoV
Urbani showed the evolution of genes (nsp5, nsp13,M, and S) that
were also shown to evolve during the emergence of SARS-CoV
from animal reservoirs. We postulate that comparison of the host
signaling and transcriptional profiles of viruses causing either at-
tenuated or lethal disease will identify signatures associated with
outcomes in both mice and humans. We demonstrate that SARS-
CoV pathogenesis is exquisitely sensitive to host immunosenes-
cence, recapitulating the disease burden seen in humans. More-
over, our model system may provide a unique probe for the
identification of early markers of immunosenescence or of broad
regulators of progressive senescence in innate and adaptive im-
mune and respiratory function. Identification of the molecular
mechanisms governing SARS-CoV disease in immunosenescence
may provide considerable opportunities for ameliorating the in-
creased disease burden associated with infections in the elderly.
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